PPT-Adjuvant Therapy for Biliary Cancer

Abby Siegel MD MS Associate Professor of Medicine Columbia University CoChair Hepatobiliary Committee SWOG NCI Task Force for Hepatobiliary Cancers Adjuvant Therapy for Biliary Cancers Models and Meta analyses. Biliary. Cancers. Abby B. Siegel, MD, MS . Columbia University. Co-Chair, SWOG . Hepatobiliary. Committee. NCI Task Force, . Hepatobiliary. Cancers. Biliary. Anatomy. Adapted from De . Groen. et al, NEJM 1999 Oct 28;341(18):1368-78 . (. CREATE-. X/JBCRG. -04. ). C. apecitabine . for. . RE. sidual. . cancer as . A. djuvant . T. h. E. rapy. San Antonio Breast Cancer Symposium, December 8-12, 2015. . Lee S-. J. 1. , Toi M. 2. , Lee E-S. Triple Negative Breast Cancer. Steven J. Isakoff, MD, PhD. Dana-Farber . Harvard Cancer . Center/ Massachusetts General Hospital Cancer . Center. August 19, 2017. sisakoff@partners.org. 46 year-old premenopausal woman . Cancer-Treatment-Induced Bone Loss (CTIBL). Clodronate and Bone Mineral Density (. Hip. ). Bone Mineral Density Substudy --ABCSG-12: Effect of Zoledronic Acid. Percent Change, Lumbar Spine. Denosumab for CTIBL (. Christy A Russell, MD. Keck School of Medicine. University of Southern California. Hazard Rate of Relapse. According to Tumor Subtype and Year of Diagnosis. British Columbia Population-Based Data. 1986-1992. Dr.Mina. . Tajvidi. . Radiation . oncologist. . Endocrine therapy in breast cancer. Endocrine therapy for hormone receptor positive early stage breast cancer in premenopausal women. Antonella Brunello . Kwok-Leung Cheung. Disclosure. No . conflict. of . interests. Learning objectives. To . discuss the pros and cons of adjuvant chemotherapy for breast cancer in the elderly. To . Heather M. Gage, MD, Avanti . Rangnekar. , Robert E. Heidel, . PhD. , Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, . PhD. The Graduate School of Medicine. The Department of Pathology. Introduction. Rajiv Doddamani. . PGY – 3, Internal Medicine . . St. Joseph Mercy Ann Arbor . Learning objectives . Explain the principles of breast cancer screenings . Professor of Medicine and Oncology. Karmanos Cancer Institute. Wayne State University. Breast Cancer 101. Biopsy +. Lumpectomy + RT. Mastectomy. SLNBx. ALND (> 3+ micro or macro preop and bx +). Standard, . Ashley E Ross, MD, PhD. Associate Professor of Urology. Northwestern University, Feinberg School of Medicine. Key Points. Genomics are independently prognostic and potentially predictive. Decipher Genomic Classifier (GC). Is less, better?. Ioannis. P. . Boukovinas. MD, PhD. ,. . PharmaD. Medical Oncologist. Bioclinic. Thessaloniki. ibouk@otenet.gr. Conflict of interest. Nothing to declare concerning this talk. X-ACT trial : . Azeez Farooki, MD. Attending Physician, Clinical Member. Memorial Sloan Kettering Cancer Center. New York, NY. Objectives. Elucidate the problem of aromatase inhibitor induced bone loss and increased risk of fractures in breast cancer. . Breast Cancer | . Epidemiology- Australia. Australian Institute of Health and Welfare 2014. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra. AIHW. Overall is the third leading cause of cancer.